May 25, 2017
Wellesley, Mass., May 25, 2017 – A new global market study by BCC Research indicates a growth trajectory above 20%-per-year in the ‘Smart Pill’ segment of the medical and pharmaceutical industry through 2021. These devices support patient monitoring, diagnostics and medicine delivery for a broad spectrum of companies.
Technologies and new uses worldwide could drive U.S. sales to reach USD $1.2 billion in annual sales by 2021 – more than twice 2016 sales levels. The industry is poised for CAGR above 20% — as much as 23% annual growth in Asia — during the next five years, according to BCC Research's Smart Pills: Applications and Global Markets.
In one example, the choice of ‘capsule endoscopy’ rather than a surgical option is creating new markets and options for doctors. Smart devices that can be swallowed are able to report on pH levels, temperature, pressure and other conditions from inside the throat, stomach and gastrointestinal tract.
"Regulatory approval is a crucial factor but the conveniences and additional information coming from smart pill applications is already showing compelling arguments,” says Robert Hunter, BCC Research editor. "These are the body’s secrets that can now be treated with better, personalized data. This has implications for cancer care, nutrition, obesity treatments for both disease and chronic care conditions, improving things between patient and doctor – using information to replace anecdotes.”
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at firstname.lastname@example.org.
Smart Pills: Applications and Global Markets( PHM181A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email email@example.com or visit www.bccresearch.com/media to request access to our library of market research.